Challenges in Prostate Biopsy

Authors

  • Mark J Ferretti Department of Urology New York Medical College New York, NY
  • Jonathan Bloom Department of Urology New York Medical College New York, NY

DOI:

https://doi.org/10.14259/tcb.v4i1.179

Keywords:

Imaging Guided Biopsy, Prostate Specific Antigen, Prostatic Neoplasms, Prostate

Abstract

Prostate cancer is a leading cause of death among US males.  Great advances have been made in the diagnosis and treatment of prostate cancer.  Particularly Prostate Specific Antigen (PSA) screening and the transrectal ultrasound-guided prostate biopsy (TRUS-BX) have been instrumental in achieving success in this field.  This mini-review analyzes challenges in regards to the prostate biopsy and diagnosis of prostate cancer.

References

Pinkhasov GI, Lin YK, Palmerola R, Smith P, Mahon F, Kaag MG, Dagen JE, Harpster LE, Reese CT, Raman JD: Complications following prostate needle biopsy requiring hospital admission or emergency department visits–experience from 1000 consecutive cases. BJU international 2012, 110:369-374.

http://dx.doi.org/10.1111/j.1464-410X.2011.10926.x

PMid:22313996

Wolf JS, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ: Best practice policy statement on urologic surgery antimicrobial prophylaxis. The Journal of urology 2008, 179:1379-1390.

http://dx.doi.org/10.1016/j.juro.2008.01.068

PMid:18280509

Vickers AJ: Four Flawed Arguments Against Prostate-specific Antigen Screening (and 1 Good One). Urology 2015, 85:491-494.

http://dx.doi.org/10.1016/j.urology.2014.11.003

PMid:25733258

Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, Karnofski K, Gulati R, Penson DF, Feuer E: Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes & Control 2008, 19:175-181.

http://dx.doi.org/10.1007/s10552-007-9083-8

PMid:18027095 PMCid:PMC3064270

Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, Colon I: The incidence of fluoroquinolone resistant infections after prostate biopsy—are fluoroquinolones still effective prophylaxis? The Journal of urology 2008, 179:952-955.

http://dx.doi.org/10.1016/j.juro.2007.10.071

PMid:18207185

Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM: Complications after prostate biopsy: data from SEER-Medicare. The Journal of urology 2011, 186:1830-1834.

http://dx.doi.org/10.1016/j.juro.2011.06.057

PMid:21944136

Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE: Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. The Journal of urology 2010, 183:963-969.

http://dx.doi.org/10.1016/j.juro.2010.02.2171

http://dx.doi.org/10.1016/j.juro.2009.11.043

PMid:20089283

Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM: Quality-of-life effects of prostate-specific antigen screening. New England Journal of Medicine 2012, 367:595-605.

http://dx.doi.org/10.1056/NEJMoa1201637

PMid:22894572

Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P: Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. European urology 2013, 63:88-96.

http://dx.doi.org/10.1016/j.eururo.2012.08.001

PMid:22902040

Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM: Radical prostatectomy versus observation for localized prostate cancer. New England Journal of Medicine 2012, 367:203-213.

http://dx.doi.org/10.1056/NEJMoa1113162

PMid:22808955 PMCid:PMC3429335

Vickers A, Bennette C, Steineck G, Adami H-O, Johansson J-E, Bill-Axelson A, Palmgren J, Garmo H, Holmberg L: Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. European urology 2012, 62:204-209.

http://dx.doi.org/10.1016/j.eururo.2012.04.024

PMid:22541389 PMCid:PMC3389180

Vickers AJ, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, Lilja H: Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. Bmj 2010, 341:c4521.

http://dx.doi.org/10.1136/bmj.c4521

PMid:20843935 PMCid:PMC2939950

Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS: Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011, 77:1035-1041.

http://dx.doi.org/10.1016/j.urology.2010.12.067

PMid:21420152

Turkbey B, Mani H, Aras O, Ho J, Hoang A, Rastinehad AR, Agarwal H, Shah V, Bernardo M, Pang Y: Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 2013, 268:144-152.

http://dx.doi.org/10.1148/radiol.13121325

PMid:23468576 PMCid:PMC3689450

Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, Khurana K, Ravizzini GC, Albert PS, Merino MJ: Prostate cancer: value of multiparametric mr imaging at 3 t for detection—histopathologifc correlation 1. Radiology 2010, 255:89-99.

http://dx.doi.org/10.1148/radiol.09090475

PMid:20308447 PMCid:PMC2843833

Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Fütterer JJ: ESUR prostate MR guidelines 2012. European radiology 2012, 22:746-757.

http://dx.doi.org/10.1007/s00330-011-2377-y

PMid:22322308 PMCid:PMC3297750

Vargas HA, Akin O, Franiel T, Goldman DA, Udo K, Touijer KA, Reuter VE, Hricak H: Normal central zone of the prostate and central zone involvement by prostate cancer: clinical and MR imaging implications. Radiology 2012, 262:894-902.

http://dx.doi.org/10.1148/radiol.11110663

PMid:22357889 PMCid:PMC3285222

Tan CH, Wei W, Johnson V, Kundra V: Diffusion Weighted Magnetic Resonance Imaging in Prostate Cancer: Meta-analysis. AJR. American journal of roentgenology 2012, 199:822.

http://dx.doi.org/10.2214/AJR.11.7805

PMid:22997374 PMCid:PMC3888871

Panebianco V, Sciarra A, Marcantonio A, Forte V, Biondi T, Laghi A, Catalano C: Conventional imaging and multiparametric magnetic resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer. The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN)[and] the International Association of Radiopharmacology (IAR),[and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2012, 56:331.

Jie C, Rongbo L, Ping T: The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis. European radiology 2014, 24:1929-1941.

http://dx.doi.org/10.1007/s00330-014-3201-2

PMid:24865693 PMCid:PMC4082652

Puech P, Potiron E, Lemaitre L, Leroy X, Haber G-P, Crouzet S, Kamoi K, Villers A: Dynamic contrast-enhanced–magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009, 74:1094-1099.

http://dx.doi.org/10.1016/j.urology.2009.04.102

PMid:19773038

Tan CH, Paul Hobbs B, Wei W, Kundra V: Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. American Journal of Roentgenology 2015, 204:W439-W448.

http://dx.doi.org/10.2214/AJR.14.13373

PMid:25794093

Garcia-Reyes K, Passoni NM, Palmeri ML, Kauffman CR, Choudhury KR, Polascik TJ, Gupta RT: Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. Abdominal imaging 2015, 40:134-142.

http://dx.doi.org/10.1007/s00261-014-0197-7

PMid:25034558 PMCid:PMC4419362

Hamoen EH, de Rooij M, Witjes JA, Barentsz JO, Rovers MM: Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta-analysis. European urology 2015, 67:1112-1121.

http://dx.doi.org/10.1016/j.eururo.2014.10.033

PMid:25466942

Sonn GA, Margolis DJ, Marks LS: Target detection: Magnetic resonance imaging-ultrasound fusion–guided prostate biopsy. In Urologic Oncology: Seminars and Original Investigations: Elsevier: 2014:903-911.

http://dx.doi.org/10.1016/j.urolonc.2013.08.006

Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, Simpfendörfer T, Huber J, Zogal P, Teber D, Pahernik S: A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. The Journal of urology 2011, 186:2214-2220.

http://dx.doi.org/10.1016/j.juro.2011.07.102

PMid:22014798

Cool DW, Zhang X, Romagnoli C, Izawa JI, Romano WM, Fenster A: Evaluation of MRI-TRUS fusion versus cognitive registration accuracy for MRI-targeted, TRUS-guided prostate biopsy. American Journal of Roentgenology 2015, 204:83-91.

http://dx.doi.org/10.2214/AJR.14.12681

PMid:25539241

Panebianco V, Barchetti F, Sciarra A, Ciardi A, Indino EL, Papalia R, Gallucci M, Tombolini V, Gentile V, Catalano C: Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. In Urologic Oncology: Seminars and Original Investigations: Elsevier: 2015:17. e11-17. e17.

Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, Marks LS: Value of targeted prostate biopsy using magnetic resonance–ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. European urology 2014, 65:809-815.

http://dx.doi.org/10.1016/j.eururo.2013.03.025

PMid:23523537 PMCid:PMC3858524

Rastinehad AR, Turkbey B, Salami SS, Yaskiv O, George AK, Fakhoury M, Beecher K, Vira MA, Kavoussi LR, Siegel DN: Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. The Journal of urology 2014, 191:1749-1754.

http://dx.doi.org/10.1016/j.juro.2013.12.007

PMid:24333515

Park BK, Park JW, Park SY, Kim CK, Lee HM, Jeon SS, Seo SI, Jeong BC, Choi HY: Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound–guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. American Journal of Roentgenology 2011, 197:W876-W881.

http://dx.doi.org/10.2214/AJR.11.6829

PMid:22021535

Tonttila PP, Lantto J, Pääkkö E, Piippo U, Kauppila S, Lammentausta E, Ohtonen P, Vaarala MH: Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy-naive men with suspected prostate cancer based on elevated prostate-specific antigen values: results from a randomized prospective blinded controlled trial. European urology 2015.

PMid:26033153

Diaz AW, Shakir NA, George AK, Rais-Bahrami S, Turkbey B, Rothwax JT, Stamatakis L, Hong CW, Siddiqui MM, Okoro C: Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. In Urologic Oncology: Seminars and Original Investigations: Elsevier: 2015:202. e201-202. e207.

Siddiqui MM, Truong H, Rais-Bahrami S, Stamatakis L, Logan J, Walton-Diaz A, Turkbey B, Choyke PL, Wood BJ, Simon RM: Clinical implications of a multiparametric magnetic resonance imaging based nomogram applied to prostate cancer active surveillance. The Journal of urology 2015, 193:1943-1949.

http://dx.doi.org/10.1016/j.juro.2015.01.088

PMid:25633923

McClure TD, Margolis DJ, Reiter RE, Sayre JW, Thomas MA, Nagarajan R, Gulati M, Raman SS: Use of MR imaging to determine preservation of the neurovascular bundles at robotic-assisted laparoscopic prostatectomy. Radiology 2012, 262:874-883.

http://dx.doi.org/10.1148/radiol.11103504

PMid:22274837

Park BH, Jeon HG, Jeong BC, Seo SI, Lee HM, Choi HY, Jeon SS: Influence of magnetic resonance imaging in the decision to preserve or resect neurovascular bundles at robotic assisted laparoscopic radical prostatectomy. The Journal of urology 2014, 192:82-88.

http://dx.doi.org/10.1016/j.juro.2014.01.005

PMid:24440235

Wink M, Frauscher F, Cosgrove D, Chapelon J-Y, Palwein L, Mitterberger M, Harvey C, Rouvière O, De La Rosette J, Wijkstra H: Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project. European urology 2008, 54:982-993.

http://dx.doi.org/10.1016/j.eururo.2008.06.057

PMid:18584944

Postema AW, Frinking PJ, Smeenge M, De Reijke TM, De la Rosette JJ, Tranquart F, Wijkstra H: Dynamic contrast‐enhanced ultrasound parametric imaging for the detection of prostate cancer. BJU international 2015.

PMid:25754526

Jeon SS, Woo S-H, Hyun J-H, Choi HY, Chai SE: Bisacodyl rectal preparation can decrease infectious complications of transrectal ultrasound-guided prostate biopsy. Urology 2003, 62:461-466.

http://dx.doi.org/10.1016/S0090-4295(03)00470-9

Sabler IM, Lazarovitch T, Haifler M, Lang E, Shapira G, Zelig S, Lindner A, Zisman A: Sterility of Reusable Transrectal Ultrasound Transducer Assemblies for Prostate Biopsy Reprocessed According to Food and Drug Administration Guidelines—Bacteriologic Outcomes in a Clinical Setup. Urology 2011, 77:17-19.

http://dx.doi.org/10.1016/j.urology.2010.06.069

PMid:21195820

Lange D, Zappavigna C, Hamidizadeh R, Goldenberg SL, Paterson RF, Chew BH: Bacterial sepsis after prostate biopsy—a new perspective. Urology 2009, 74:1200-1205.

http://dx.doi.org/10.1016/j.urology.2009.07.1222

PMid:19815258

Lorber G, Benenson S, Rosenberg S, Gofrit ON, Pode D: A single dose of 240 mg gentamicin during transrectal prostate biopsy significantly reduces septic complications. Urology 2013, 82:998-1003.

http://dx.doi.org/10.1016/j.urology.2013.01.074

PMid:23992970

Luong B, Danforth T, Visnjevac O, Suraf M, Duff M, Chevli KK: Reduction in Hospital Admissions With the Addition of Prophylactic Intramuscular Ceftriaxone Before Transrectal Ultrasonography–guided Prostate Biopsies. Urology 2015, 85:511-516.

http://dx.doi.org/10.1016/j.urology.2014.10.047

PMid:25596154

Liss MA, Peeples AN, Peterson EM: Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. Journal of clinical microbiology 2011, 49:1116-1118.

http://dx.doi.org/10.1128/JCM.01885-10

PMid:21177893 PMCid:PMC3067719

Duplessis CA, Bavaro M, Simons MP, Marguet C, Santomauro M, Auge B, Collard DA, Fierer J, Lesperance J: Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 2012, 79:556-563.

http://dx.doi.org/10.1016/j.urology.2011.09.057

PMid:22386395

Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J: Fluoroquinolone‐resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound‐guided prostate biopsy—should we reassess our practices for antibiotic prophylaxis? Clinical Microbiology and Infection 2012, 18:575-581.

http://dx.doi.org/10.1111/j.1469-0691.2011.03638.x

PMid:21958149

Taylor S, Margolick J, Abughosh Z, Goldenberg SL, Lange D, Bowie WR, Bell R, Roscoe D, Machan L, Black P: Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. BJU international 2013, 111:946-953.

http://dx.doi.org/10.1111/j.1464-410X.2012.11637.x

PMid:23464844

Liss MA, Kim W, Moskowitz D, Szabo RJ: Comparative effectiveness of targeted vs empirical antibiotic prophylaxis to prevent sepsis from transrectal prostate biopsy: a retrospective analysis. The Journal of urology 2015, 194:397-402.

http://dx.doi.org/10.1016/j.juro.2015.03.110

PMid:25846415

Jones JS, Oder M, Zippe CD: Saturation prostate biopsy with periprostatic block can be performed in office. The Journal of urology 2002, 168:2108-2110.

http://dx.doi.org/10.1016/S0022-5347(05)64307-8

http://dx.doi.org/10.1097/00005392-200211000-00050

PMid:12394720

Zisman A, Leibovici D, Kleinmann J, Cooper A, Siegel Y, Lindner A: The impact of prostate biopsy on patient well-being: a prospective study of voiding impairment. The Journal of urology 2001, 166:2242-2246.

http://dx.doi.org/10.1016/S0022-5347(05)65543-7

http://dx.doi.org/10.1097/00005392-200112000-00049

PMid:11696744

Carey JM, KORMAN HJ: Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications? The Journal of urology 2001, 166:82-85.

http://dx.doi.org/10.1097/00005392-200107000-00020

http://dx.doi.org/10.1016/S0022-5347(05)66082-X

Downloads

Published

2016-04-09

Issue

Vol. 4 No. 1 (2016): March, 2016

Section

Mini Reviews